vs

Side-by-side financial comparison of Cellectis S.A. (CLLS) and FLEXIBLE SOLUTIONS INTERNATIONAL INC (FSI). Click either name above to swap in a different company.

Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $9.1M, roughly 1.0× FLEXIBLE SOLUTIONS INTERNATIONAL INC). FLEXIBLE SOLUTIONS INTERNATIONAL INC runs the higher net margin — -5.1% vs -265.9%, a 260.8% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -0.5%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-4.0M).

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

Flexible Solutions International Inc develops and manufactures specialty chemicals for water conservation, energy efficiency, and agricultural use. Core products include water body evaporative reduction solutions, farm crop yield additives, and swimming pool heat retention products, serving customers across North America and global agricultural markets.

CLLS vs FSI — Head-to-Head

Bigger by revenue
CLLS
CLLS
1.0× larger
CLLS
$9.5M
$9.1M
FSI
Growing faster (revenue YoY)
CLLS
CLLS
+375.5% gap
CLLS
375.0%
-0.5%
FSI
Higher net margin
FSI
FSI
260.8% more per $
FSI
-5.1%
-265.9%
CLLS
More free cash flow
CLLS
CLLS
$31.6M more FCF
CLLS
$27.6M
$-4.0M
FSI

Income Statement — Q2 FY2024 vs Q4 FY2025

Metric
CLLS
CLLS
FSI
FSI
Revenue
$9.5M
$9.1M
Net Profit
$-25.3M
$-460.9K
Gross Margin
29.4%
Operating Margin
-181.1%
11.6%
Net Margin
-265.9%
-5.1%
Revenue YoY
375.0%
-0.5%
Net Profit YoY
-51.9%
-167.8%
EPS (diluted)
$-0.28
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLLS
CLLS
FSI
FSI
Q4 25
$9.1M
Q3 25
$10.6M
Q2 25
$11.4M
Q1 25
$7.5M
Q4 24
$9.2M
Q3 24
$9.3M
Q2 24
$9.5M
$10.5M
Q1 24
$9.2M
Net Profit
CLLS
CLLS
FSI
FSI
Q4 25
$-460.9K
Q3 25
$-503.4K
Q2 25
$2.0M
Q1 25
$-277.7K
Q4 24
$679.6K
Q3 24
$611.9K
Q2 24
$-25.3M
$1.3M
Q1 24
$457.2K
Gross Margin
CLLS
CLLS
FSI
FSI
Q4 25
29.4%
Q3 25
23.9%
Q2 25
47.4%
Q1 25
26.1%
Q4 24
29.2%
Q3 24
40.9%
Q2 24
37.4%
Q1 24
30.6%
Operating Margin
CLLS
CLLS
FSI
FSI
Q4 25
11.6%
Q3 25
2.9%
Q2 25
29.0%
Q1 25
-0.9%
Q4 24
9.4%
Q3 24
20.5%
Q2 24
-181.1%
18.7%
Q1 24
8.3%
Net Margin
CLLS
CLLS
FSI
FSI
Q4 25
-5.1%
Q3 25
-4.8%
Q2 25
17.8%
Q1 25
-3.7%
Q4 24
7.4%
Q3 24
6.6%
Q2 24
-265.9%
12.3%
Q1 24
5.0%
EPS (diluted)
CLLS
CLLS
FSI
FSI
Q4 25
$-0.03
Q3 25
$-0.04
Q2 25
$0.15
Q1 25
$-0.02
Q4 24
$0.05
Q3 24
$0.05
Q2 24
$-0.28
$0.10
Q1 24
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLLS
CLLS
FSI
FSI
Cash + ST InvestmentsLiquidity on hand
$149.0M
Total DebtLower is stronger
$4.4M
Stockholders' EquityBook value
$148.6M
$38.9M
Total Assets
$407.1M
$61.8M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLLS
CLLS
FSI
FSI
Q4 25
Q3 25
Q2 25
$10.0M
Q1 25
$11.0M
Q4 24
$10.0M
Q3 24
$13.0M
Q2 24
$149.0M
$9.2M
Q1 24
$8.3M
Total Debt
CLLS
CLLS
FSI
FSI
Q4 25
$4.4M
Q3 25
$7.1M
Q2 25
$7.5M
Q1 25
$8.1M
Q4 24
$8.8M
Q3 24
$9.4M
Q2 24
$8.3M
Q1 24
$8.0M
Stockholders' Equity
CLLS
CLLS
FSI
FSI
Q4 25
$38.9M
Q3 25
$39.0M
Q2 25
$39.4M
Q1 25
$38.4M
Q4 24
$38.0M
Q3 24
$36.9M
Q2 24
$148.6M
$36.2M
Q1 24
$36.0M
Total Assets
CLLS
CLLS
FSI
FSI
Q4 25
$61.8M
Q3 25
$58.4M
Q2 25
$58.2M
Q1 25
$61.7M
Q4 24
$60.0M
Q3 24
$57.8M
Q2 24
$407.1M
$56.3M
Q1 24
$57.6M
Debt / Equity
CLLS
CLLS
FSI
FSI
Q4 25
0.11×
Q3 25
0.18×
Q2 25
0.19×
Q1 25
0.21×
Q4 24
0.23×
Q3 24
0.25×
Q2 24
0.23×
Q1 24
0.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLLS
CLLS
FSI
FSI
Operating Cash FlowLast quarter
$28.9M
$-3.0M
Free Cash FlowOCF − Capex
$27.6M
$-4.0M
FCF MarginFCF / Revenue
290.5%
-44.3%
Capex IntensityCapex / Revenue
13.2%
11.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-591.7K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLLS
CLLS
FSI
FSI
Q4 25
$-3.0M
Q3 25
$2.0M
Q2 25
$5.3M
Q1 25
$-544.3K
Q4 24
$-2.2M
Q3 24
$2.5M
Q2 24
$28.9M
$5.9M
Q1 24
$-604.8K
Free Cash Flow
CLLS
CLLS
FSI
FSI
Q4 25
$-4.0M
Q3 25
$39.4K
Q2 25
$4.3M
Q1 25
$-898.4K
Q4 24
$-4.3M
Q3 24
$1.3M
Q2 24
$27.6M
$4.7M
Q1 24
$-1.1M
FCF Margin
CLLS
CLLS
FSI
FSI
Q4 25
-44.3%
Q3 25
0.4%
Q2 25
37.9%
Q1 25
-12.0%
Q4 24
-47.0%
Q3 24
13.6%
Q2 24
290.5%
44.9%
Q1 24
-11.7%
Capex Intensity
CLLS
CLLS
FSI
FSI
Q4 25
11.7%
Q3 25
18.7%
Q2 25
8.6%
Q1 25
4.7%
Q4 24
22.8%
Q3 24
13.0%
Q2 24
13.2%
11.3%
Q1 24
5.2%
Cash Conversion
CLLS
CLLS
FSI
FSI
Q4 25
Q3 25
Q2 25
2.60×
Q1 25
Q4 24
-3.27×
Q3 24
4.05×
Q2 24
4.59×
Q1 24
-1.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons